Study examines perceptions of the risk of driving while under the influence of cannabis Cannabis Psychology Research Marijuana Impaireddriving Riskperception iaapsy UofT uOttawa
Perceiving driving under the influence of cannabis as dangerous or risky has been found to decrease the likelihood of engaging in the behavior. Cannabis usage and potency have increased in the US and Canada, while perceived harm has decreased. Studies have shown that despite a decrease in perceived risk associated with cannabis use, there is still an increased risk of collisions and impaired driving behavior and performance.
The data used in this study were obtained from the Centre for Addiction and Mental Health Monitor 2017, a telephonic survey of adults in Canada that is regionally stratified and cross-sectional in design. The CAMH Monitor is performed quarterly using independent samples of around 750 completions each. The study focused on individuals who had used cannabis in the past year and provided responses about their perceptions of the risk of DUIC.
Related StoriesTwo survey items were used to measure the objective of using cannabis, which served as the focal exposure variable. The survey question inquired about the frequency of cannabis, hash, or marijuana usage within the last year. The second question was directed only to those who reported using cannabis in the past year and asked if they had used cannabis for medical purposes such as managing pain, glaucoma, nausea, multiple sclerosis symptoms, or other medical conditions.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
The new Scottish adventure that’s part computer game, part night safariPsychedelic visions of cows are common, but rarer sightings of pine martens and even wildcats are a possibility
Read more »
Topical cannabidiol is well tolerated in individuals with a history of elite physical performance and chronic lower extremity pain - Journal of Cannabis ResearchIntroduction Cannabidiol (CBD) is a potential therapeutic for pain management. Yet, there exists a dearth of studies of its tolerability and efficacy, especially in special populations. Former elite athletes are a special population both susceptible to chronic pain and also highly trained and attuned to assess medication tolerability concerns. The purpose of the present open-label pilot study was to assess the tolerability of CBD in this population. Materials and methods Retrospective analysis was conducted in deidentified data from 20 individuals who were all previously professional athletes in US/American football, track and field, or basketball, with careers ranging from 4 to 10 years. Participants received topical CBD (10 mg twice daily by controlled dispenser) for chronic pain resulting from acute lower extremity injuries. Assessments of tolerability and secondary analyses of pain, pain-related disability, and activities of daily living were collected by self-report over the 6-week study period. Data were analyzed by descriptive statistics, pairwise t-test, and linear regression. Results Seventy percent of participants completed the study. Of the individuals who completed the study, 50% reported minor adverse effects, none of which required medical attention, and 50% did not report any adverse effects. The mostly commonly reported effects were skin dryness (43% of study completers) and skin rash (21% of study completers), which rapidly resolved. There was a significant improvement in self-reported pain levels (intake mean 3.5 ± 0.29; exit mean 1.7 ± 0.23; P | 0.001) and pain-related disability, including family and home responsibilities, life support activities, occupational activities, recreational activities, self-care, sexual function, and social activities (all P | 0.001). Discussion To the best of our knowledge, this is the first study to assess CBD treatment in elite athletes, who are disproportionally susceptible to disabling injuries. Topical administra
Read more »
Research uncovers alternate mechanism for producing key protein in metastatic prostate cancerLike the better-known prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA) is a biomarker that can tell physicians much about a patient's metastatic prostate cancer. PSMA is a protein on the cell surface of most prostate cancers; scanning for it with positron emission tomography (PET) can indicate where in the body prostate cancer has spread, and it can be targeted with a newly approved radioactive therapy. In 15%–20% of patients with castration-resistant prostate cancer, however, PSMA production stops at advanced stages of the disease.
Read more »
Pop-up clinic coming to Corby to research dementia, cancers and moreIt is part of a huge health research programme and is one of 19 new clinic locations opening in April
Read more »
Study highlights the potential long-term neurological effects post-COVID-19Study highlights the potential long-term neurological effects post-COVID-19 biorxivpreprint neurological postcovid COVID19 covid SARSCoV2 neurologicaleffects symptoms news research spikeproteins sprotein
Read more »
Study develops a novel model that estimates undetected COVID-19 emergenceStudy develops a novel model that estimates undetected COVID-19 emergence PLOSONE BeALonghorn covid COVID19 SARSCoV2 emergence news novel methods model epidemic pandemic health publichealthnews
Read more »